New antibiotics for Gram-negative pneumonia
Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2022-12-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/31/166/220119.full |
| _version_ | 1797961023486951424 |
|---|---|
| author | Matteo Bassetti Federica Magnè Daniele Roberto Giacobbe Lorenzo Bini Antonio Vena |
| author_facet | Matteo Bassetti Federica Magnè Daniele Roberto Giacobbe Lorenzo Bini Antonio Vena |
| author_sort | Matteo Bassetti |
| collection | DOAJ |
| description | Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treating patients with pneumonia is challenging and must be guided by in vitro susceptibility results. In this review, we provide an overview of antibiotics newly approved for the treatment of pneumonia caused by Gram-negative bacilli. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam have potent activity against some of the carbapenem-resistant Enterobacterales, especially Klebsiella pneumoniae carbapenemase producers. Several novel antibiotics have potent activity against multidrug-resistant Pseudomonas aeruginosa, such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused by Acinetobacter baumannii, along with plazomicin and eravacycline. |
| first_indexed | 2024-04-11T00:52:54Z |
| format | Article |
| id | doaj.art-107e0a3a8d0a47979362cc2ae2ff9406 |
| institution | Directory Open Access Journal |
| issn | 0905-9180 1600-0617 |
| language | English |
| last_indexed | 2024-04-11T00:52:54Z |
| publishDate | 2022-12-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | European Respiratory Review |
| spelling | doaj.art-107e0a3a8d0a47979362cc2ae2ff94062023-01-05T07:48:23ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172022-12-013116610.1183/16000617.0119-20220119-2022New antibiotics for Gram-negative pneumoniaMatteo Bassetti0Federica Magnè1Daniele Roberto Giacobbe2Lorenzo Bini3Antonio Vena4 Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treating patients with pneumonia is challenging and must be guided by in vitro susceptibility results. In this review, we provide an overview of antibiotics newly approved for the treatment of pneumonia caused by Gram-negative bacilli. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam have potent activity against some of the carbapenem-resistant Enterobacterales, especially Klebsiella pneumoniae carbapenemase producers. Several novel antibiotics have potent activity against multidrug-resistant Pseudomonas aeruginosa, such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused by Acinetobacter baumannii, along with plazomicin and eravacycline.http://err.ersjournals.com/content/31/166/220119.full |
| spellingShingle | Matteo Bassetti Federica Magnè Daniele Roberto Giacobbe Lorenzo Bini Antonio Vena New antibiotics for Gram-negative pneumonia European Respiratory Review |
| title | New antibiotics for Gram-negative pneumonia |
| title_full | New antibiotics for Gram-negative pneumonia |
| title_fullStr | New antibiotics for Gram-negative pneumonia |
| title_full_unstemmed | New antibiotics for Gram-negative pneumonia |
| title_short | New antibiotics for Gram-negative pneumonia |
| title_sort | new antibiotics for gram negative pneumonia |
| url | http://err.ersjournals.com/content/31/166/220119.full |
| work_keys_str_mv | AT matteobassetti newantibioticsforgramnegativepneumonia AT federicamagne newantibioticsforgramnegativepneumonia AT danielerobertogiacobbe newantibioticsforgramnegativepneumonia AT lorenzobini newantibioticsforgramnegativepneumonia AT antoniovena newantibioticsforgramnegativepneumonia |